

Risk Sharing Agreements in Resource constraint environments – provider perspective

Praneet Valodia

Executive Manager: Innovation and Development, ICON

Disclaimer

This presentation reflects my own views on risk sharing and does not reflect the views of the government or any other organization or committee that I am affiliated with.

Provider Perspective

- Improve access to quality cancer care in resource constrained environment
- 80% of private oncologists in SA are contracted to ICON


ICON's approach

- Towards equity
 - Cost awareness, efficiency gains and reduce wastage
 - Costing of clinical protocols
 - Clinical pathways / formulary
 - Re-imburement linked to benefits
 - Rational use of medicines - EBM
 - Pharmaco-economic evaluation
- Towards improved outcomes
 - Treatment Protocols by treatment intent
- Towards patient-centricity
 - Integrated Continuum of Cancer Care Model

Risk sharing schemes

- Financial based
 - price-volume arrangements / budget impact scheme
 - Based on payback mechanism
- Outcomes/performance-based

Outcomes-based re-imburement



Pros: outcomes-based model

- Improve access to new, innovative drugs
- Outcomes-based approach
- Build clinical experience with medicines
- Opportunities for partnership

Barriers: outcomes-based model

- early access to new medicines with as yet unproven efficacy and safety
- specific objective outcomes for clinical measures not always in place
- burdensome administration (high costs)
- rules and conditions to participating providers
- ethics and confidentiality issues
- cost of managing therapeutic failures

Role of ICON in Risk Sharing

- Selection of medicines for RSS
- Validated measurement tools
- Provide IT systems for monitoring in RS
- Develop system for real world data collection
- Provide reports on outcomes (independent adjudication)

Challenges with measuring health outcomes

- Careful planning of data collection
- A priori specification of confounding variables
- Availability of good baseline information
- Missing data points
- Clinical and statistical differences

ICON views on RSS

Before entering into a risk sharing arrangement:

- SEP should be reasonable in relation to the international benchmarks
- product should offer value-for-money
- Increase access to as many patients as possible

Closing remarks

RSS can provide patients with some hope of gaining access to the newest therapies

RSS between pharma and funder – clinicians provide clinical expertise in enhancing outcomes

Pilot with provider involvement